The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool



Olsson-Brown, Anna, Piskilidis, Pavlos, O'Hagan, Julie, Thorp, Nicky, Robson, Peter, Innes, Helen, Wong, Helen, Cicconi, Silvia ORCID: 0000-0001-5507-6203, Jackson, Richard, Kiernan, Tamara
et al (show 3 more authors) (2019) The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool. BREAST, 44. pp. 94-100.

[thumbnail of CP FINAL Sept 2018  Olsson-Brown et al 2018.pdf] Text
CP FINAL Sept 2018 Olsson-Brown et al 2018.pdf - Author Accepted Manuscript

Download (732kB)
[thumbnail of CP FINAL complete Figures for oncotype paper.pdf] Text
CP FINAL complete Figures for oncotype paper.pdf - Author Accepted Manuscript

Download (752kB)

Abstract

<h4>Purpose</h4>The 21-gene recurrence score (Oncotype DX) (RS) informs systemic therapy decision making in ER-positive HER2-negative early breast cancer (BC). To date no study has described the more nuanced discussions that take place regarding systemic therapy or the impact of the RS on concordance in such decision making. Here we utilized a novel decision making tool to assess the impact of the RS on decision making as well as concordance of treatment recommendations.<h4>Patients and methods</h4>The clinicopathological information (CPI) of 50 BCs without and with the RS were presented to a panel of breast oncologists in a simulated MDT. The Liverpool Adjuvant Systemic Therapy Decision Tool (LASTDT) was developed and used to categorize treatment recommendations. Outcome measures included the impact of the RS on decisiveness and concordance in decision making and its impact on treatment recommendations.<h4>Results</h4>Availability of the RS increased definitive decision making from 8% (4/50) to 56% (28/50) [χ<sup>2</sup> = 79.35, p < 0.001] and altered the LASTDT category in 68% (34/50) of cases (p < 0.001), 74% of which were to forgo chemotherapy. With knowledge of RS, universal concordance rose from 14% to 64% [K = 0.328: K = 0.729].<h4>Conclusions</h4>The RS improves certainty of decision making as well as concordance amongst oncologists. This provides evidence that the availability of the RS can improve consistency of decision making amongst oncologists and thus helps to ensure patients are managed consistently. This is particularly important when patients are managed in a loco-regional, multidisciplinary team manner where heterogeneous decisions can lead to disparity in care.

Item Type: Article
Uncontrolled Keywords: Breast cancer, 21 gene recurrence score, MDT, Decision making
Depositing User: Symplectic Admin
Date Deposited: 09 Apr 2019 08:56
Last Modified: 19 Jan 2023 00:54
DOI: 10.1016/j.breast.2019.01.005
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3036239